Last updated: June 26, 2026
Avanir Pharmaceuticals Inc. v. Wockhardt Ltd. (1:12-cv-01125) Litigation Summary and Patent Strategy Analysis
What was the Avanir v. Wockhardt case (1:12-cv-01125) about?
Avanir Pharmaceuticals Inc. sued Wockhardt Ltd. in the U.S. District Court for the District of Delaware under the Hatch-Waxman framework in 1:12-cv-01125, challenging the patentability and/or infringement risk tied to Wockhardt’s planned generic/ANDA entry for Avanir’s branded CNS product.
Because this request specifies only the case caption and docket number, the litigation summary and infringement analysis must be based on the case-specific record. No further case-record facts can be produced from the information provided.
What patents were asserted in Avanir v. Wockhardt (1:12-cv-01125)?
Not available from the provided input.
What was Wockhardt’s ANDA/Paragraph IV posture in 1:12-cv-01125?
Not available from the provided input.
What did the court decide in Avanir v. Wockhardt, and when?
Not available from the provided input.
How do settlement or consent judgment dynamics affect generic entry risk in this case?
Not available from the provided input.
Which claims survived, what defenses were raised, and what was the infringement/validity reasoning?
Not available from the provided input.
What generic launch risks exist for Avanir’s product because of this litigation?
Not available from the provided input.
How strong is the patent estate implied by the litigation outcome?
Not available from the provided input.
How does this case compare with other Avanir patent litigations against generics?
Not available from the provided input.
Key Takeaways
Not available from the provided input.
FAQs
- What is the typical Delaware forum impact for Hatch-Waxman disputes like 1:12-cv-01125?
- How does a Paragraph IV notice shape the timing and scope of Avanir v. Wockhardt-style litigation?
- What claim types (composition, method-of-use, formulation) most often drive outcomes in Avanir CNS generics disputes?
- How do court claim constructions usually affect generic infringement analyses in ANDA cases?
- What settlement terms most commonly govern generic launch timing in Hatch-Waxman actions?
References
No sources were provided, and no case-record identifiers (orders, complaints, claim lists, or docket entries) were supplied to support citation.
